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Abstract: Recently, genetic alterations in the genes encoding succinate dehydrogenase subunit B 
and D (SDHB and SDHD) were identified in pet dogs that presented with spontaneously arising 
pheochromocytomas (PCC) and paragangliomas (PGL; together PPGL), suggesting dogs might be 
an interesting comparative model for the study of human PPGL. To study whether canine PPGL 
resembled human PPGL, we investigated a series of 50 canine PPGLs by immunohistochemistry to 
determine the expression of synaptophysin (SYP), tyrosine hydroxylase (TH) and succinate 
dehydrogenase subunit A (SDHA) and B (SDHB). In parallel, 25 canine PPGLs were screened for 
mutations in SDHB and SDHD by Sanger sequencing. To detect large chromosomal alterations, 
single nucleotide polymorphism (SNP) arrays were performed for 11 PPGLs, including cases for 
which fresh frozen tissue was available. The immunohistochemical markers stained positive in the 
majority of canine PPGLs. Genetic screening of the canine tumors revealed the previously described 
variants in four cases; SDHB p.Arg38Gln (n = 1) and SDHD p.Lys122Arg (n = 3). Furthermore, the 
SNP arrays revealed large chromosomal alterations of which the loss of chromosome 5, partly 
homologous to human chromosome 1p and chromosome 11, was the most frequent finding (100% 
of the six cases with chromosomal alterations). In conclusion, canine and human PPGLs show 
similar genomic alterations, suggestive of common interspecies PPGL-related pathways. 
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1. Introduction 
Pheochromocytomas (PCCs) and paragangliomas (PGLs; together PPGLs) are tumors arising 
from chromaffin tissue inside (PCC) and outside the adrenal glands (PGL). These tumors occur in the 
context of several hereditary syndromes, such as Von Hippel Lindau (VHL), Multiple Endocrine 
Neoplasia type 2, Neurofibromatosis type 1, and the PCC-PGL syndrome, with underlying germline 
mutations in the VHL, rearranged during transfection (RET), neurofibromin 1 (NF1), and the SDH-
genes, respectively [1]. Both germline and somatic mutations can be found in more than 20 genes 
[2,3]. Although approximately 10% of PPGL patients, in general, will present with (distant) 
metastases, this frequency is much higher in patients with succinate dehydrogenase subunit B 
(SDHB) germline mutations. During follow-up, more than 35% of SDHB patients will present with 
PPGL metastases [4,5].  
In an effort to unravel the mechanisms behind malignant behavior of PPGLs, and more 
specifically the metastatic behavior of SDHB-related tumors, several attempts have been made to 
generate knock-out mouse models. These models either proved lethal during embryogenesis or the 
mice did not develop PPGL or other SDH-related tumors [6]. The only mouse models that presented 
with high frequencies of PCCs were based on conditional homozygous inactivation of Pten and 
heterozygous conventional inactivation of Nf1 [7]. However, human PPGLs have never been 
associated with phosphatase and tensin homolog (PTEN) mutations [8]. In addition, NF1-related 
PPGLs are relatively benign with metastatic behavior seen in fewer than 10% of cases [9]. So, although 
these PPGL mouse models are interesting, there remains a need for an appropriate animal model to 
study SDH-related PPGL.  
Recently, Holt et al. reported genetic screening of eight canine PPGLs and identified four genetic 
variants that might be potentially pathogenic; one in SDHB (p.Arg38Gln) and three in succinate 
dehydrogenase subunit D (SDHD; p.Lys122Arg), of which one was somatic [10]. Because these 
alterations occurred in highly conserved amino acids, the authors assumed that the alterations were 
likely pathogenic. In fact, the somatic event suggests that at least the SDHD p.Lys122Arg amino acid 
change is likely pathogenic, while the SDHB alteration remains of unknown significance. Since this 
is the first animal model that presents spontaneously with PPGL that might be related to SDHB and 
SDHD mutations, we have investigated a relatively large series of canine PPGLs by Sanger 
sequencing for mutations in these genes. In addition, immunohistochemistry was performed for 
tyrosine hydroxylase, synaptophysin, SDHB, and succinate dehydrogenase subunit A (SDHA), and 
SNP arrays to identify chromosomal alterations.  
2. Results 
2.1. Clinical Findings 
The canine PPGL immunohistochemistry series included 32 PCCs and 18 PGLs. The average age 
of the dogs at diagnosis was 11 years for PCCs (ranging from 4 to 16 years) and 9 years for PGLs 
(ranging from 2 to 11 years). In the PCC group, the distribution of males and females was almost 
identical (53% male), while the PGL group included more tumors from males (72%). Metastatic 
behavior was reported in 3% of the dogs with PCCs (n = 1) and 11% of the dogs with PGL (n = 2).  
2.2. Genetic Analyses 
Sanger sequencing results are shown in Table 1. Twenty-one PPGLs (20 PCCs and one PGL) with 
sufficient DNA quality and positive synaptophysin (SYP) or tyrosine hydroxylase (TH) 
immunohistochemical labeling, were screened for mutations in the SDHB and SDHD genes. If a 
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tumor had a non-synonymous variant, the presence of this variant was also investigated in 
corresponding germline DNA.  
Three PCCs showed an SDHD (XM_536573) c.365A>G; p.Lys122Arg alteration. In PCC6 and 
PCC46 the variant was homozygous, while in PCC23 the alteration was heterozygous. Germline 
DNA was only available for PCC6 and showed the SDHD variant in a heterozygous fashion, 
indicating loss of the wild type (WT) SDHD allele in the tumor (Figure 2), which was also confirmed 
by the loss of heterozygosity analyses for microsatellite markers flanking the SDHD gene (Figure 1B). 
PCC19 showed the previously described SDHB (NM_001252217) c.113G>A; p.Arg38Gln alteration, 
which appeared homozygous in the tumor and corresponding germline DNA of this dog. (Figure 1A) 
In addition, genetic screening for SDHA mutations was only performed in SDHA 
immunohistochemically-negative tumor PCC1 (see below Figure 2). Due to the relatively poor 
quality of the sample it was not possible to obtain SDHA DNA sequences of sufficient quality to 
analyze.  
2.3. Immunohistochemistry  
SYP was positive in 86% of PCCs and 71% of PGLs, while TH was positive in 74% of PCCs and 
35% of PGLs. Results of the immunohistochemistry of all tumors are listed in Supplemental Table S1 
and illustrated in Figure 1. SDHB immunohistochemistry was performed on all 50 canine PPGLs. 
PCC1 and PCC6 showed heterogeneous labeling for SDHB, with foci of tumor cells that were 
immunohistochemically negative for SDHB and areas that were weakly positive. The SDHA labeling 
for PCC1 also appeared to be negative for the tumor cells in this PCC (Figure 2), while all other tumors 
were positive. All other PPGLs, as well as the positive control tissues (normal dog adrenals), were 
immunohistochemically positive, although they did not show the typical granular labeling pattern.  
2.4. SNP Arrays 
Chromosomal alterations were investigated for 11 dog PPGLs by SNP arrays. From those, 
analysis was not possible for two samples due to high background noise. In addition, three tumors 
did not show any chromosomal alterations. The chromosomal alterations of the six remaining tumors 
are listed in Table 2. Furthermore, an illustrative single nucleotide polymorphism (SNP) array result 
of case PCC20 (logR ratios and b-allele frequencies (BAF)) is depicted in Figure 1C, showing loss of 
chromosomes 5, 17, 23, 26, 30, and 34. The most frequent genomic alteration was loss of chromosome 
5, which occurred in all six dog PPGLs (100%), followed by loss of chromosome 26 in 5/6 dog PPGLs 
(83%). Chromosome 5 (CanFam3.1) is, for a large part, syntenic to two areas of human chromosome 
1 (GRCh38.p3), and to a part of human chromosome 11, including the SDHD region, respectively (see 
Figure 3, Supplemental Table S3). Genomic locations of SDHA, SDHB, SDHC, and SDHD are shown 
in Supplemental Figure S2.  
  
Cancers 2019, 11, 607 4 of 11 
 
 
Figure 1. (A) In the left panel, succinate dehydrogenase subunit B (SDHB) sequences are displayed 
from healthy reference (upper), PCC19, and corresponding germline DNA. In the right panel, the 
succinate dehydrogenase subunit D (SDHD) sequence is shown from healthy reference, PCC6, and 
corresponding germline DNA. Note that PCC19 tumor and germline DNA both show the SDHB 
c.113G>A; p.Arg38Gln variant. PCC6 shows SDHD c.365A>G; p.Lys38Arg in a homozygous fashion 
in the tumor DNA and heterozygous in the germline DNA, indicating loss of the wild type allele in 
the tumor. (B) Shows loss of heterozygosity of the larger allele in PCC6, confirming the Sanger 
sequencing results. (C) The SNP array result of PCC 20 displays in the upper panel logR ratios, 
indicating loss of chromosomes 5, 17, 23, 26, 30, and 34. This is also seen in the lower panel by the B-
allele frequencies. 
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Figure 2. Hematoxylin Eosin staining and immunohistochemistry for synaptophysin (SYP), tyrosine 
hydroxylase (TH), succinate dehydrogenase subunit A (SDHA) and subunit B (SDHB) of normal dog 
adrenal, PCC1, and PCC6. Normal adrenal glands were used as positive controls and show strong 
expression of SYP and tyrosine hydroxylase (TH). PCC1 and 6 label weakly positive for SYP, but for 
TH only PCC1 shows positive labeling. The normal canine adrenal gland labels positive for SDHA 
and SDHB, although there is lack of granular labeling, which is characteristic for SDHA and SDHB in 
human tissues. PCC1 shows labeling of the stromal cells for SDHA and SDHB, which serve as positive 
control cells, while the PCC cells appear to be heterogeneous weak/negative for SDHB and do not 
label for SDHA. PCC 6 showed heterogeneous weak expression of SDHB, but there was no difference 
in labeling intensity between the tumor cells and the normal stromal cells for SDHA. Pictures are at 
20× magnification, internal boxes at 40× magnification.   
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Figure 3. Homology between dog chromosome 5 and 26, and the human genome. It shows the 
homology between dog chromosome 5 and 26 and several human chromosomes. Of note is that the 
SDHD gene is located on dog chromosome 5 (see Supplemental Figure S2). 
Table 1. Variants identified by Sanger Sequencing. SDH-variants that were previously described by 
Holt et al. [10] as mutations are depicted in bold and italic. If a non-synonymous variation was 
detected in the tumor, the corresponding germline was investigated for the presence of the variant.  
PCC 
Number SDHB Synonymous 
SDHB  
Non-Syn 
SDHD 
Syn 
SDHD  
Non-Syn Comment 
PCC1 p.Y50Y, p.Q164Q, p.A210A  WT   
PCC2 p.Y150Y, p.Q164Q, p.A210A  WT   
PCC3 WT  WT   
PCC4 p.A210A  WT   
PCC5 p.Y150Y, p.Q164Q, p.L188L, p.A210A  WT   
PCC6 p.Y150Y, p.Q164Q, p.A210A  p.A97A p.K122RHO/HE LOH confirmed 
PCC9 p.Y150Y, p.Q164Q, p.A210A  WT   
PCC10 p.Y150Y, p.Q164Q, p.A210A  WT   
PCC11 p.L188L  WT   
PCC13 p.L188L  WT   
PCC14 p.L188L  WT   
PCC15 p.Y150Y, p.Q164Q, p.L188L, p.A210A  WT   
PCC16 p.L188L  WT   
PCC17 WT  WT   
PCC18 p.L188L  WT   
PCC19 p.Y150Y, p.Q164Q, p.A210A p.R38QHO/HO WT  loss Chr. 5 
PCC20 p.L188L  WT  loss Chr. 5 
PCC21 p.Y150Y, p.Q164Q, p.L188L, p.A210A  WT   
PCC22 p.Y150Y, p.Q164Q, p.L188L, p.A210A  WT   
PCC23 p.Y150Y, p.Q164Q, p.L188L, p.A210A  p.A97A p.K122RHE  
PCC46 NA  WT p.K122RHO loss Chr.5 
HO = homozygous in tumor (PCC46); HE = heterozygous in tumor (PCC23); HO/HE = homozygous 
in variant in tumor, heterogeneous in germline; HO/HO = homozygous variant in both tumor and 
germline; LOH = loss of heterozygosity in tumor, loss of chromosome 5 detected with the SNP array 
are indicated in the comments, non-syn = non-synonymous, syn = synonymous. 
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Table 2. Summary of single nucleotide polymorphism (SNP) array results. 
Chromosome PCC19 PCC20 PCC36 * PCC37 * PCC43 * PCC46 * 
2     LOSS  
3     LOSS  
5 LOSS LOSS LOSS LOSS LOSS LOSS 
7 LOSS   LOSS  LOSS 
8     LOSS  
9   GAIN    
12     LOSS  
15     LOSS  
16     LOSS LOSS 
17 LOSS LOSS     
18     LOSS  
20    LOSS LOSS  
21     LOSS  
22     LOSS  
23  LOSS     
25     LOSS  
26 LOSS LOSS LOSS  LOSS LOSS 
27       
28       
29     LOSS  
30 LOSS LOSS     
31 LOSS    LOSS  
32 LOSS  LOSS  LOSS  
34 LOSS LOSS     
35 LOSS    LOSS  
Overview of large chromosomal changes in the informative dog PPGL. * Noisy sample 
3. Discussion 
Currently, there is still no curative therapy for patients with metastatic PPGL. In general, 
malignant behavior occurs in 10% of patients with PPGL. However, patients with SDHB germline 
mutations have a much higher chance of developing distant metastases [11]. Investigating animal 
models of PPGL could lead to the development and testing of therapies for humans with metastatic 
PPGL. Thus far, the only animal model that presents with metastatic PCC is a Pten KO mouse [12,13]. 
Since PTEN mutations do not play a role in the pathogenesis of human (malignant) PPGL, such 
models are not the most suitable for the study of human malignant PPGL [8]. A recent study reported 
that dogs presenting spontaneously with PPGL had potential pathogenic genetic alterations in SDHB 
and SDHD [10]. To investigate these results in an independent and larger series we have screened 25 
canine PPGLs for mutations and identified one SDHB and three non-synonymous SDHD genetic 
alterations, both of which have been described previously [10].  
The SDHD p.Lys122Arg variant was identified in three canine PPGLs; once in a heterozygous 
(PCC23) and twice in a homozygous fashion (PCC6 and PCC46). The corresponding germline DNA 
from PCC6 showed the variant to be present in a heterozygous fashion, indicating loss of the wild 
type SDHD allele in the tumor DNA. This finding was confirmed by the loss of heterozygosity (LOH) 
analysis, using microsatellites flanking the SDHD gene. Although there was no germline DNA 
available for PCC46, the homozygous expression of the SDHD p.Lys122Arg variant in the tumor 
could be explained by the potential loss of the SDHD wild type, since the SNP array results showed 
loss of chromosome 5, which includes the SDHD gene. However, this is only speculation, since we 
cannot confirm the possibility that the SDHD variant was heterozygous in the germline DNA, and 
could also be present as a homozygous SDHD p.Lys122Arg or homozygous wild type.  
In addition, another previously described non-synonymous SDHB variant [10] was detected in 
PCC19. This tumor showed the SDHB p.Arg38Gln variant in a homozygous fashion, which was also 
homozygous in DNA isolated from normal tissue from the same dog. Although the SDHB p.Arg38 
is a highly conserved amino acid throughout many species, the fruit fly has a Gln at position 38. Since 
the variant was already present in a homozygous fashion in the germline, no loss of the SDHB locus 
was seen in the SNP array results. As the p.Arg38Gln amino acid change is probably not deleterious 
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to the function of the protein, we regard this variant as likely benign. However, this should be further 
investigated functionally. 
Sanger sequencing screening of this tumor did not reveal any novel mutations in SDHB and 
SDHD. However, mutations could have been missed due to the poor DNA quality, resulting in 
sequences that could not be analyzed, and due to other driving mechanisms, such as promoter-
methylation or large (exon) deletions, which are not detectable by Sanger sequencing [14–16]. 
The SDHA and SDHB immunohistochemistry appeared to be positive in almost all investigated 
tumors, with the exception of PCC1 and PCC6. PCC1 also was immunohistochemically negative for 
SDHA. However, since the positive control tissues (normal dog adrenals) showed homogeneous and 
not granular cytoplasmic labeling, we suspect that the antibody is not suitable for screening for SDH 
mutations, as in human PPGL [17,18], and, therefore, no conclusions can be drawn from the SDHA 
and SDHB immunohistochemistry. In addition, the negative/weak positive SDHA and SDHB 
labeling could also be due to technical limitations, such as fixation artifacts. 
The SNP array results showed large chromosomal alterations in six of the nine PPGLs with 
informative SNP arrays. The fact that three tumors did not show chromosomal aberrations was most 
likely due to the low neoplastic cell content of these frozen tissue samples, from which DNA was 
isolated. From the six tumors that showed chromosomal alterations, loss of chromosome 5 was the 
most frequent alteration (100%). Canine chromosome 5 shows homology with regions of human 
chromosome 1p and 11q. Many studies have shown that loss of chromosome 1p and chromosome 11 
are frequent events in the pathogenesis of human PPGL [3,19,20]. Our results suggest that there are 
common genes, located in these homologous chromosomal areas, that might contribute to the 
pathogenesis of both human and canine PPGL.  
4. Materials and Methods  
4.1. Patients and Sample Selection  
In total, we collected 50 dog PPGLs from 45 dogs (including one case with bilateral tumors), 
which comprised of 44 formalin-fixed paraffin wax-embedded (FFPE) blocks and six fresh frozen 
samples (FF), from contributing Veterinary faculties from the University of Bristol, Bristol, United 
Kingdom (n = 25), Utrecht University, Utrecht, the Netherlands (n = 12), University of Zurich, Zurich, 
Switzerland (n = 8), and University of Bologna, Bologna, Italy (n = 5) . In addition, we also collected 
three normal canine adrenal glands provided by the Veterinary Faculty of Utrecht University, to be 
used as positive controls for the immunohistochemistry. In addition, from two dogs, corresponding 
germline DNA was available (PCC6 and PCC19). All tissue samples were collected during surgery 
or necropsy examination from pet dogs suffering from PPGL. The owners of the dogs had given 
permission for the tissues to be used for research purposes. All clinical characteristics including age, 
breed, and gender are listed in Supplemental Table S1. PPGLs were only considered malignant if 
distant metastases were present, as for human PPGL. A summary of the current study is shown in 
Supplemental Figure S1.  
4.2. Immunohistochemistry 
Immunohistochemistry was performed for all canine samples to confirm the diagnosis of PPGL 
using markers for synaptophysin (SYP) and tyrosine hydroxylase (TH). SYP and TH were evaluated 
by Esther Korpershoek and Daphne Dieduksman and scored as positive if there was a weak to strong 
specific expression in the cytoplasm of all tumor cells. SYP was labeled using the Ventana Benchmark 
ULTRA automated immunohistochemistry stainer (details available on request), while TH 
immunohistochemistry was performed as previously described [13]. Since in human PPGL, negative 
SDHB immunohistochemistry reliably identifies tumors with mutations in SDHA, SDHB, SDHC, or 
SDHD, we also investigated the immunohistochemical expression of SDHB in the canine PPGLs [21]. 
The peptide to which this SDHB antibody was generated is 99% homologous to the canine peptide; 
only one of 108 amino acid residues is different. The series of canine PPGLs was also labeled for 
SDHA, as described previously [17]. Normal dog adrenal glands were used as positive controls for 
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immunohistochemistry. The immunohistochemistry was performed on 5 μm sections using the 
Ventana automated stainer as described previously [18]. SDHB and SDHA expression was scored as 
positive if strong expression was observed in all cells, while a tumor was considered as negative if 
the labeling of the tumor cells was negative or weakly positive compared with the positive granular 
labeling present in the surrounding endothelial cells, which serve as internal positive controls [17,21]. 
4.3. Genetic Screening 
In total, 24 PPGLs (Supplemental Table S1) that expressed SYP and/or TH 
immunohistochemically were selected for the genetic screening and one TH/SYP negative PCC was 
also studied. For the FFPE samples, DNA isolation was performed by manual microdissection, to 
ensure that the DNA was derived from a high percentage of neoplastic cells. DNA isolation was 
performed with the DNaesy kit (#69504, Qiagen, Venlo, the Netherlands) according to the 
manufacturer’s protocol. DNA concentrations were measured with the Qubit® dsDNA HS BR assay 
kit (#Q32850, Thermo Fisher, Waltham, MA, USA) according to the manufacturer’s instructions. For 
the generation of the primers, human SDHA (NM_004168), SDHB (NM_003000), and SDHD 
(MN_003002) mRNA sequences were aligned with the dog genome (CanFam3.1/canFam3) to identify 
the exact location and sequences of the genes and exons, enabling the generation of dog-specific 
primers covering all of the coding sequences. PCR was performed with KAPA2G Hotstart Readymix 
(#KK5004, Sopachem, Ochten, the Netherlands) for which conditions were optimized per primer pair 
and are listed, together with the primer sequences, in Supplemental Table S2. In total, 21 DNA 
samples were of sufficient quality to be screened for mutations. Due to technical limitations, we were 
unable to investigate exon 1 and 8 of SDHB, and exon 1 and 2 of SDHD. Sanger sequencing was 
performed as previously described [17].  
4.4. Loss of Heterozygosity 
To confirm the loss of the wild type allele in SDHD-mutated samples, LOH analysis was 
performed using two microsatellite markers located upstream and downstream from the dog SDHD 
gene. Primer sequences and PCR conditions are indicated in Supplemental Table S2. Furthermore, 
PCR was performed as previously described [17]. 
4.5. SNP Arrays: 
To determine the chromosomal alterations present in dog PCC, we performed SNP arrays on 11 
canine PPGLs (Table 2). Canine HD Beadchip SNP arrays (#WG-440-1001, Illumina, San Diego, CA, 
USA) with a high resolution genome-wide coverage (170,000 SNPs; resolution of approximately 15 
SNPs per Mb) were performed and analyzed according to standard procedures at the Human 
Genomics Facility (HuGeF), Erasmus MC, University Medical Center Rotterdam 
(www.glimdna.org).  
Final report output files, containing B-allele frequencies and logR ratios, were generated using 
Illumina BeadStudio Software. The processed files were accordingly visualized using Nexus Copy 
Number software package (V7.5; Biodiscovery, El Segundo, CA, USA). The SNP array results were 
submitted to the Gene Expression Omnibus Database. Noisy samples that clearly showed a drop or 
gain in B-allele frequencies and logR of entire chromosomes were still included in the analysis, taking 
into account the risk of missing subtle chromosomal changes. 
5. Conclusions 
In conclusion, the results of the current study indicate that similar genomic alterations occur in 
canine and human PPGLs. Although more functional proof is required to classify the pathogenicity 
for the SDHD p.Lys122Arg variant, our data suggest that this variant could potentially be pathogenic. 
Since chromosomal alterations occurred in the dog PPGL at high frequency, affecting chromosomes 
that are homologous to regions that are also repeatedly lost in human PPGLs, we propose that canine 
PPGLs are an interesting model for the study of the pathogenesis of human PPGL [22]. More studies 
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are required to identify which common pathways are involved in the pathogenesis of PPGL in both 
humans and dogs.  
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